

Trial Name	Protocol #	PI	Study Team	Enrolling sites	Key Eligibility & Screening	Treatment Arms
Neo-adjuvant/Adjuvant Trials						
Neo-adjuvant Pembro for Merkel Cell Carcinoma	UPCC 01622	Dr. John Miura	CRC: Shraya Divaker CRNs: Jennifer Tabita-Martinez & Lydia Giles	HUP; Valley Forge; Lancaster General Health; Duke University	clinical stage I-III MCC	1 dose of pembro + definitive Sx + 1 yr pembro
					Must have adequate tumor burden to yield 2-4 pre-operative research bx	
					ECOG PS 0 or 1 No active CNS metastases and/or carcinomatous meningitis; brain MRI required	
Adjuvant Cemiplimab for SCC	UPCC 04619	Dr. Joanna Walker	CRC: Santosh Yendapalli, Melanie Maron	HUP	pathologic resected cSCC: primary lesion, primary with nodal involvement, or nodal metastasis with known primary	Arm A: adjuvant cemiplimab up to 48 wks
					completion of curative intent post-op RT within 2-6 wks of randomization	
					non-cutaneous SCC not eligible	
					no other concurrent malignancy other than localized cSCC within 3 yrs of randomization	Arm B: placebo up to 48 wks
					no hematologic malignancies	
					no history of distantly metastatic cSCC	
no autoimmune diseases						
no prior systemic anti-cancer immunotherapy for cSCC						
Metastatic 1st Line Trials						
RADVAX for Metastatic Melanoma	UPCC 05618	Dr. Tara Mitchell	CRC: Carrie Bosse CRNs: Jennifer Tabita-Martinez & Lydia Giles	HUP; Valley Forge; Lancaster General Health; Huntsman Cancer Institute	histologically confirmed metastatic melanoma (includes CNS mets)	Arm A: Ipi/Nivo
					≥ 2 measurable lesions per RECIST 1.1	
					HFRT index lesion 1-7 cm	Arm B: Ipi/Nivo + radiation
					prior adjuvant αCTLA4 excluded CNS mets – symptomatic or require urgent local therapy are excluded	
Metastatic 2nd Line Trials						
LIMIT for Metastatic Melanoma	UPCC 01620	Dr. Ravi Amaravadi	CRC: Carrie Bosse CRNs: Jennifer Tabita-Martinez & Lydia Giles	HUP	unresectable stage III or IV melanoma ≥ 1 measurable site of disease by RECIST v.1.1 not previously irradiated allowed for refractory pts per 3.2.4 treated brain mets allowed if > 2 wks post gamma knife, surgery or stable 2 months post whole brain RT stable corticosteroid dose x 1 month or tapering off and reached 20 mg prednisone or equivalent	Phase IIC: Nivo + Rela + HCO (pts must be αPD-1 refractory)

Key
 ipi= ipilimumab
 nivo= nivolumab
 rela= relatlimab
 pembro= pembrolizumab
 HCO= hydroxychloroquine